DE69029528D1 - Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie - Google Patents

Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie

Info

Publication number
DE69029528D1
DE69029528D1 DE69029528T DE69029528T DE69029528D1 DE 69029528 D1 DE69029528 D1 DE 69029528D1 DE 69029528 T DE69029528 T DE 69029528T DE 69029528 T DE69029528 T DE 69029528T DE 69029528 D1 DE69029528 D1 DE 69029528D1
Authority
DE
Germany
Prior art keywords
functional derivatives
adhesion molecule
intercellular adhesion
molecule icam
antivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69029528T
Other languages
English (en)
Other versions
DE69029528T2 (de
Inventor
Timothy Alan Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BLOOD RES CENTER
Original Assignee
BLOOD RES CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BLOOD RES CENTER filed Critical BLOOD RES CENTER
Publication of DE69029528D1 publication Critical patent/DE69029528D1/de
Application granted granted Critical
Publication of DE69029528T2 publication Critical patent/DE69029528T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69029528T 1989-03-16 1990-03-08 Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie Expired - Lifetime DE69029528T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32407389A 1989-03-16 1989-03-16
US45429289A 1989-12-22 1989-12-22

Publications (2)

Publication Number Publication Date
DE69029528D1 true DE69029528D1 (de) 1997-02-13
DE69029528T2 DE69029528T2 (de) 1997-06-26

Family

ID=26984265

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69029528T Expired - Lifetime DE69029528T2 (de) 1989-03-16 1990-03-08 Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
DE69033983T Expired - Lifetime DE69033983T2 (de) 1989-03-16 1990-03-08 Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69033983T Expired - Lifetime DE69033983T2 (de) 1989-03-16 1990-03-08 Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie

Country Status (13)

Country Link
EP (2) EP0391088B1 (de)
JP (1) JP3166854B2 (de)
KR (1) KR0178024B1 (de)
AT (2) ATE146968T1 (de)
AU (1) AU648016B2 (de)
CA (1) CA2012125C (de)
DE (2) DE69029528T2 (de)
DK (2) DK0745852T3 (de)
ES (2) ES2097748T3 (de)
GR (1) GR3022846T3 (de)
HK (1) HK1003104A1 (de)
HU (1) HU220235B (de)
NZ (1) NZ232920A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
DK0387668T3 (da) * 1989-03-09 1997-03-03 Blood Res Center Intercellulært adhæsionsmolekyle-2 og dets bindende ligander
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
DE69131564T2 (de) * 1990-07-20 2000-01-13 Bayer Ag Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
EP0510483A1 (de) * 1991-04-22 1992-10-28 Boehringer Ingelheim Pharmaceuticals Inc. Verfahren zum Nachweis von Viren
EP0650367A4 (de) * 1992-06-01 1998-04-15 New England Medical Center Inc Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen.
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
WO1995027736A1 (en) * 1994-04-12 1995-10-19 Boehringer Ingelheim Pharmaceuticals, Inc. Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection
AU698406B2 (en) * 1994-04-19 1998-10-29 University Of Kansas, The ICAM-1/LFA-1 short-chain peptides and method of using same
AU1122697A (en) * 1995-11-22 1997-06-11 Research And Development Institute, Inc. Therapeutic and diagnostic agents for the treatment of microbial infections
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997032596A1 (en) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Intercellular adhesion molecule powder formulation
US6075004A (en) * 1996-04-26 2000-06-13 The University Of Kansas Peptide compositions which induce immune tolerance and methods of use
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
AU777241B2 (en) 1999-06-24 2004-10-07 Johns Hopkins University, The Compositions and methods for preventing transepithelial transmission of HIV
GB0216729D0 (en) * 2002-07-18 2002-08-28 Glaxo Group Ltd Animal models

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949B1 (de) * 1987-05-04 1995-10-04 Dana Farber Cancer Institute Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
WO1990003400A1 (en) * 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Also Published As

Publication number Publication date
HK1003104A1 (en) 1998-10-09
HU220235B (hu) 2001-11-28
ATE146968T1 (de) 1997-01-15
DE69033983T2 (de) 2003-03-20
AU5129490A (en) 1990-09-20
CA2012125A1 (en) 1990-09-16
ES2177695T3 (es) 2002-12-16
CA2012125C (en) 2003-07-29
ATE219838T1 (de) 2002-07-15
HUT56133A (en) 1991-07-29
EP0745852A1 (de) 1996-12-04
DE69033983D1 (de) 2002-08-01
EP0391088B1 (de) 1997-01-02
JPH0372430A (ja) 1991-03-27
EP0391088A3 (de) 1991-10-02
GR3022846T3 (en) 1997-06-30
KR0178024B1 (ko) 1999-03-20
JP3166854B2 (ja) 2001-05-14
EP0745852B1 (de) 2002-06-26
KR900013984A (ko) 1990-10-22
DK0745852T3 (da) 2002-10-14
HU901585D0 (en) 1990-06-28
DE69029528T2 (de) 1997-06-26
AU648016B2 (en) 1994-04-14
EP0391088A2 (de) 1990-10-10
ES2097748T3 (es) 1997-04-16
NZ232920A (en) 1997-05-26
DK0391088T3 (da) 1997-06-16

Similar Documents

Publication Publication Date Title
DE69033983D1 (de) Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
DE69008664D1 (de) Bestrahlung von bluterzeugnissen.
DE3781240D1 (de) Vorrichtung zur stimulation von gliedversteifungen.
DE3854700D1 (de) Verwendung von wässrigen kationischen Kunststoffdispersionen zum Imprägnieren und Grundieren von saugfähigen Substraten.
GR3006073T3 (de)
FI875544A0 (fi) Anvaendning av 3'-deoxitymidin-2'-en (3'-deoxi-2',3'-didehydrotymidin) foer behandling av patienter infekterade med retrovirus.
DE3751576D1 (de) Virale Inaktivierung und Reinigung von aktiven Proteinen.
BR8707096A (pt) Projetil comportando subprojeteis com zona de eficacia predefinida
DE3767550D1 (de) Oberflaechenbehandlung von titangegenstaenden.
DE3885913D1 (de) Aufbereitung von Alkoxysilanen.
DE68910320D1 (de) Behandlung von holz und auf holz basierenden stoffen.
DE3675654D1 (de) Nach amplitude ausgeglichenes und anpassbarer laser.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
ATE143058T1 (de) Typisierung humaner rhinoviren
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE3863093D1 (de) Sulfosuccinamidsaeuren von polyoxypropylendiaminen und ihre verwendung als emulgatoren.
DE3769332D1 (de) Derivate von pyrido-menadion-additionsprodukten und verwendungen davon.
DE3886765D1 (de) Derivate von synergimycinen a und b.
DE69002234D1 (de) Ultraschallbehandlung von teigerzeugnissen.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE69430188T2 (de) Behandlung von hiv-infektionen mittels huminsäure
ATE81454T1 (de) Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.
DE3788424D1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).
NO873102L (no) Modifiserte virale glykoproteiner, samt diagnostiske og terapeutiske anvendelser derav.
ATE62678T1 (de) Derivate von pyrido-menadion-additionsprodukten und verwendungen davon.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition